WO2005005449A2 - Steroid modified solatrioses - Google Patents
Steroid modified solatrioses Download PDFInfo
- Publication number
- WO2005005449A2 WO2005005449A2 PCT/EP2004/007538 EP2004007538W WO2005005449A2 WO 2005005449 A2 WO2005005449 A2 WO 2005005449A2 EP 2004007538 W EP2004007538 W EP 2004007538W WO 2005005449 A2 WO2005005449 A2 WO 2005005449A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- compound
- formula
- group
- yield
- Prior art date
Links
- 0 CO[C@@](C(C*)O[C@](C1*)S*)C1O* Chemical compound CO[C@@](C(C*)O[C@](C1*)S*)C1O* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Definitions
- the present invention relates to the chemical synthesis of alkaloid glycosides, in particular to the synthesis of steroid modified solatrioses. Furthermore, the present invention relates to novel steroid modified solatrioses and intermediate compounds useful for the synthesis thereof.
- Solasodine and its glycosides are of considerable interest commercially and clinically. They are widely used as starting products for the synthesis of various steroidal drugs.
- the aglycon solasodine is a source for synthetic cortisone and progesterone.
- solasodine glycosides have potent antineoplastic properties.
- triglycoside solasonine 22R, 25R
- the structure of this triglycoside is as follows:
- the above triglycoside is conventionally obtained by extraction from a plant source.
- a commercially available extract of S. sodomaeum commonly referred to as BEC (Drug Future, 1988, vol. 13.8, pages 714-716) is a crude mixture of solamargine, solasonine and their isomeric diglycosides.
- the extraction process for making BEC involves homogenizing the fruits of S. sodomaeum in a large volume of acetic acid, filtering off the liquid through muslin followed by precipitation of the glycosides with ammonia (Drugs of today (1990), Vol. 26 No. 1 , p. 55-58, cancer letters (1991), Vol. 59, p. 183-192).
- the yield of the solasodine glycoside mixture is very low (approx. 1%).
- the individual process steps are not defined to GMP in terms of scale up, definition of yield, composition and product quality.
- the steroid skeleton of solasodine contains a very labile nitrogen-containing ring.
- the steroid ring systems of relared alkaloids such as tomatidine, demissidine or solanidine.
- These aglycons cannot readily be chemically modified while keeping the steroid skeleton intact.
- the prior art does not disclose the synthesis of the solasonine using the aglycon material as starting material.
- solasonine requires the stereoselective glycosylation of solasodine at the relatively unreactive hydroxyl group.
- solasodine is not compatible with the conventional steroid glycosylation technique. No glycosylation was observed following the treatment of solasodine with tetrabenzoyl ⁇ -D-glucopyranosyl trichloroacetimidate and trimethyl- silyl triflate or boron trifluoride dietherate (unpublished results).
- the problem underlying the present invention is to provide a cost effective method for the preparation of solasonine and solasonine analogues in high yields.
- the present invention provides a method for the preparation of a steroid modified solatriose of general formula (I):
- R 1 represents a steroid or a derivative thereof having a hydroxyl group in 3- position and no further unprotected hydroxyl groups
- R 2 represents a straight or branched C-M alkyl group or a hydroxyl group.
- the method of the present invention comprises the step of: reacting a compound of general formula (XIII):
- the compound of the above general formula (XV) may be transformed to the desired steroid modified solatriose of general formula (I) by any suitable method known in the art. A particular preferred procedure is described in detail below.
- the present application provides steroid modified solatriose compounds of general formula (I) as defined above, wherein R 1 represents a tomatidin-3-yl, demissidin-3-yl, solanidin-3-yl or solasodin-3-yl group.
- a further object of the present application is the provision of intermediate compounds useful for the synthesis of the steroid modified solatriose of general formula (I) defined above, namely:
- R 6 , R 8 and R 9 are as defined above; and R 5 represents a straight or branched C 1 - 14 alkyl group or a phenyl group optionally substituted with one or more C- 1 - 4 alkyl groups, halogen atom such as Cl, F, Br or I, or NO 2 group.
- R 5 represents a straight or branched C 1 - 14 alkyl group or a phenyl group optionally substituted with one or more C- 1 - 4 alkyl groups, halogen atom such as Cl, F, Br or I, or NO 2 group.
- the steroid residue constituting substituent R 1 is a steroid or a derivative thereof having a hydroxyl group in the 3-position for bonding as ⁇ -glycosidic hydroxyl group in the compound of general formula (I).
- the steroid residue bears no further unprotected hydroxyl groups and preferably has no further hydroxyl groups at all, in order not to compromise subsequent reaction steps.
- R 1 is selected from a tomatidin-3-yl, demissidin-3-yl, solanidin- 3-yl and solasodin-3-yl group.
- All of those steroid groups contain a labile nitrogen-containing ring and, therefore, cannot be chemically modified by means of conventional methods. Moreover, all of the above steroid groups represent substituents for cyctotoxic, anti bacterial, anti fungal or anti viral compounds.
- each R 2 independently represents a straight or branched alkyl group having 1 to 4 carbon atoms or a hydroxyl group. In a preferred embodiment, R 2 represents a methyl group.
- step (A) galactose is reacted in step (A) to yield a compound of general formula (II):
- R 3 represents a chlorine or bromine atom; and each R 4 independently represents a benzoyl, acetyl or pivolyl protecting group.
- R 3 represent a bromine atom.
- R 4 represents an acetyl protecting group.
- Step (A) may be carried out using either acetic anhydride, acetyl chloride, benzoyl chloride, benzoic anhydride, or pivolyl chloride in the presence of a base such as, e.g., pyridine, triethylamine, or collidine, to give fully esterified galactose.
- a base such as, e.g., pyridine, triethylamine, or collidine
- Esterified- D-galactopyranose may be treated with hydrogenbromide or hydrogenchloride in glacial acetic acid to yield the above compound of general formula (II).
- galactose is suspended in organic base such as pyridine and cooled to 0°C, to this solution is added dropwise either acetic anhydride, benzoic anhydride or acid chloride . Upon complete addition the solution is warmed to +25°C (room temperature) and stirred for about 16 hours. The reaction is quenched by addition of alcohol. The solution is diluted with organic solvent such as tert-butylmethyl ether, or dichloromethane, or toluene and washed with cold 1 N HCI, water, saturated sodium bicarbonate, water and brine then the product is dried over magnesium sulfate and concentrated under reduced pressure to dryness. The product can be used without further purification or it can be recrystallised.
- the fully esterified galactopyranose in dry solvent such as dichloromethane is cooled to O°C under an inert atmosphere.
- dry solvent such as dichloromethane
- hydrogen bromide typically 30% HBr content.
- the solution is allowed to warm to +25°C (room temperature) and stirred for around 16 hours.
- the solution is diluted with organic solvent such as dichloromethane and then quickly washed with ice cold water, saturated aqueous sodium bicarbonate, and brine.
- the product is dried over magnesium sulfate filtered and the solvent is removed under reduced pressure.
- the product is crystallized from petrol (40-60) and diethyl ether.
- step (B) a compound of general formula (II) is reacted with a compound of general formula (III): HS-R 5 Formula (III) wherein R 5 represents a straight or branched C 1 - 14 alkyl group or a phenyl group optionally substituted with one or more C 1 - 4 alkyl groups; whereby the C1-14 alkyl groups are preferably selected from methyl, ethyl and propyl and the phenyl group is preferably selected form phenyl, p-methylphenyl and p-chlorophenyl; and methyl, ethyl and propyl are particularly preferred; to yield a compound of general formula (IV):
- R 5 is a phenyl group.
- step (C) the compound of general formula (IV) is deprotected to yield a compound of general formula (V):
- deprotection condition conventionally employed in the chemistry of protecting groups may be used.
- Deprotection is preferably be carried out in an inert organic solvent such as dichloromethane or tetrahydrofuran in the presence of an alkali metal alkoxide having 1 to 4 carbon atoms and a C 1 - 4 alcohol, or in the presence of water, an alkali metal hydroxide and a C 1 - 4 alcohol.
- deprotection in step (C) is carried out in dry methanol with catalytic amount of sodium methoxide.
- step (D) the OH group in 6-position is selectively protected in step (D) using a bulky protecting group to yield a compound of general formula (VI)
- R 5 is as defined above; and R 6 is a pivolyl, benzoyl or substituted benzoyl protecting group, whereby the substituents are selected from alkyl groups such as methyl, halogen atoms such as Cl, Br, F,and I and NO 2 .
- R 6 represents a pivolyl protecting group.
- reaction may be carried out using pivolyl chloride in dry dichloromethane in the presence of pyridine.
- step (E) the OH groups in 3- and 4-position are selectively protected with a ketal or acetal protecting group using standard conditions to yield a compound of general formula (VII):
- R 7 represents a ketal or acetal protecting group selected from benzylidene, 4-nitrobenzylidene, 4- methoxybenzylidene or isopropylidene.
- R 7 represents an isopropylidene protecting group.
- the reaction is preferably carried out in a dipolar aprotic solvent such as dimethyl formamide (DMF) or acetone in the presence of acid catalysts such as p-toluene sulfonic acid or camphorsulfonic acid using a 2,2-dialkyloxypropane or an optionally substituted dialkylbenzylidene.
- a dipolar aprotic solvent such as dimethyl formamide (DMF) or acetone
- acid catalysts such as p-toluene sulfonic acid or camphorsulfonic acid using a 2,2-dialkyloxypropane or an optionally substituted dialkylbenzylidene.
- Suitable reaction temperatures range from ambient temperature to elevated temperatures.
- the reaction is carried out at a temperature of 25°C.
- step (F) the OH group in 2-position is protected in step (F) by reacting the compound of general formula (VII) with chloroacetyl chloride to yield a compound of general formula (VIII):
- the reaction may be carried out in a dry solvent such as dichloromethane with a base such as pyridine or triethylamine at a temperature of from 0°C to 25°C.
- a dry solvent such as dichloromethane
- a base such as pyridine or triethylamine
- step (G) the compound of general formula (VIII) is deprotected to yield a compound of general formula (IX):
- Deprotection may be carried out under acidic conditions by treating with aqueous acetic acid, aqueous trifluoroacetic acid or mineral or sulfonic acid.
- step (H) the compound of general formula (IX) is reacted with a trialkylorthoacetate, benzoate or pivolate, wherein the alkyl residues have 1 to 4 carbon atoms, to form an 3,4-ortho ester which is subsequently migrated to the axial 4-position under acidic conditions to yield a compound of general formula (X):
- R 9 is an acetyl, benzoyl or pivolyl protecting group.
- R 9 represent an acetate or benzoyl protecting group, which may be introduced by means of trimethyl or triethyl orthoacetate or benzoate, most preferably trimethylorthoacetate.
- Step (H) may be conducted in an inert organic solvent such as acetonitrile.
- the reaction is carried out in the presence of a catalyst.
- a catalyst Any conventional catalyst used in carbohydrate chemistry may be employed.
- Particular preferred catalysts include p-toluenesulfonic acid, or camphor sulfonic acid. The most preferred catalyst is p-toluenesulfonic acid.
- the reaction may preferably be carried out under anhydrous conditions in the presence of a water detracting means such as 4A mol sieves.
- step (I) The free OH group in 3-position is reacted in step (I) with a protected halogen glucose derivative of general formula (XI):
- a protected halogen glucose derivative of general formula (XI) Formula (XI) wherein R 4 is as defined above; and R 10 represent a halogen atom such as fluorine, chlorine or bromine, to yield a compound of general formula (XII):
- R >4 4 , R D5°, R ⁇ p , R B and R 9 are as defined above.
- the reaction is preferably carried out in the presence of promoters such as silver triflate, zinc dichloride, borontrifluoride diethyletherate, or N-iodosuccinamide/triflic acid.
- promoters such as silver triflate, zinc dichloride, borontrifluoride diethyletherate, or N-iodosuccinamide/triflic acid.
- a dry solvent such as dichloromethane is employed.
- the reaction temperature is preferably at a range of from -20°C to 25°C.
- Activating compound (XII) may be achived in step (J) through the oxidiation of the thio ether to the sulfoxide and the formation of the anomer trifate of general formula (XIII) below, which may exist as either the alpha triflate or the alpha ion pair: Formula (XIII) wherein R >4 , D R5 , D R6 , D R8 and R are as defined above.
- the reaction is preferably carried out by oxidizing the thio ether group to a sulfoxide using hydrogen peroxide, and subsequently treating the resulting intermediate with triflic anhydride.
- a sterically hindered non-nucleophilic base such as 2,6-lutidine, 2,4,6-collidine or 2,6-di-tertbutyl- 4-methyl-pyridine is present.
- the most preferred sterically hindered base is 2,6-di- tertbutyl-4-methly-pyridine.
- step (K) coupling of the compound of general formula (XIII) with the compound of general formula (XIV) HO-R 1 Formula (XIV) wherein R 1 is as defined above; may be performed in the presence of sterically hindered non-nucleophilic base such as 2,6-l ⁇ tidine, 2,4,6-collidine or 2,6-di-tertbutyl- 4-methyl pyridine, preferably 2,6-di-tertbutyl-4-methyl-pyridine, to yield a compound of general formula (XV):
- sterically hindered non-nucleophilic base such as 2,6-l ⁇ tidine, 2,4,6-collidine or 2,6-di-tertbutyl- 4-methyl pyridine, preferably 2,6-di-tertbutyl-4-methyl-pyridine
- the reaction is carried out at low temperature such as 0°C or lower, more preferably -10°C or lower.
- the most preferred reaction temperature is -20°C.
- step (L) the OH group in 2-position substituted with R 8 is selectively deprotected using thio urea in the presence of a sterically hindered base such as 2,6-lutidine, 2,4,6-collidine or 2,6-di-tertbutyI-4-methyl pyridine, preferably 2,6-lutidine, in a dry alcohol such as methanol, ethanol or isopropanol, preferably ethanol, and subsequently reacted with a protected halogen rhanmose derivative of general formula (XVI):
- a sterically hindered base such as 2,6-lutidine, 2,4,6-collidine or 2,6-di-tertbutyI-4-methyl pyridine, preferably 2,6-lutidine
- a dry alcohol such as methanol, ethanol or isopropanol, preferably ethanol
- step (M) may be performed under substantially the same conditions as described above for step (C) to yield the compound of general formula (I).
- deesterification may by accomplished using sodium methoxide in a methanol/dichloromethane mixture.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04763140A EP1644391A2 (en) | 2003-07-08 | 2004-07-08 | Steroid modified solatrioses |
JP2006518156A JP2009513527A (en) | 2003-07-08 | 2004-07-08 | Steroid-modified solatriose |
US10/563,745 US20090012013A9 (en) | 2003-07-08 | 2004-07-08 | Steroid modified solatrioses |
CA002529358A CA2529358A1 (en) | 2003-07-08 | 2004-07-08 | Steroid modified solatrioses |
AU2004255352A AU2004255352A1 (en) | 2003-07-08 | 2004-07-08 | Steroid modified solatrioses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03015501 | 2003-07-08 | ||
EP03015501.4 | 2003-07-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005005449A2 true WO2005005449A2 (en) | 2005-01-20 |
WO2005005449A3 WO2005005449A3 (en) | 2005-04-21 |
Family
ID=34042822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/007538 WO2005005449A2 (en) | 2003-07-08 | 2004-07-08 | Steroid modified solatrioses |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090012013A9 (en) |
EP (1) | EP1644391A2 (en) |
JP (1) | JP2009513527A (en) |
AU (1) | AU2004255352A1 (en) |
CA (1) | CA2529358A1 (en) |
WO (1) | WO2005005449A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003018604A1 (en) * | 2001-08-21 | 2003-03-06 | Glycomed Sciences Limited | Synthesis of solanum glycosides |
WO2003030884A2 (en) * | 2001-10-09 | 2003-04-17 | Glycomed Sciences Limited | Use of solasonine for the treatment of skin tumors |
WO2004096830A1 (en) * | 2003-04-30 | 2004-11-11 | Glycomed Sciences (Uk) Limited | Synthesis of solanum glycosides |
WO2005005454A1 (en) * | 2003-07-08 | 2005-01-20 | Glycomed Sciences Limited | Steroid modified chacotrioses and solatrioses |
-
2004
- 2004-07-08 EP EP04763140A patent/EP1644391A2/en not_active Withdrawn
- 2004-07-08 US US10/563,745 patent/US20090012013A9/en not_active Abandoned
- 2004-07-08 JP JP2006518156A patent/JP2009513527A/en active Pending
- 2004-07-08 WO PCT/EP2004/007538 patent/WO2005005449A2/en active Application Filing
- 2004-07-08 AU AU2004255352A patent/AU2004255352A1/en not_active Abandoned
- 2004-07-08 CA CA002529358A patent/CA2529358A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003018604A1 (en) * | 2001-08-21 | 2003-03-06 | Glycomed Sciences Limited | Synthesis of solanum glycosides |
WO2003030884A2 (en) * | 2001-10-09 | 2003-04-17 | Glycomed Sciences Limited | Use of solasonine for the treatment of skin tumors |
WO2004096830A1 (en) * | 2003-04-30 | 2004-11-11 | Glycomed Sciences (Uk) Limited | Synthesis of solanum glycosides |
WO2005005454A1 (en) * | 2003-07-08 | 2005-01-20 | Glycomed Sciences Limited | Steroid modified chacotrioses and solatrioses |
Non-Patent Citations (6)
Title |
---|
IKEDA T ET AL: "Synthesis of neosaponins having an alpha-l-rhamnopyranosyl-(1->4)-Äal pha-l-rhamnopyranosyl-(1->2)Ü-d-glucopyran osyl glyco-linkage" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 42, no. 12, 18 March 2001 (2001-03-18), pages 2353-2356, XP004229921 ISSN: 0040-4039 * |
JOHNS, TIMOTHY ET AL: "Glycoalkaloids of Solanum series Megistacrolobum and related potato cultigens" BIOCHEMICAL SYSTEMATICS AND ECOLOGY , 14(6), 651-5 CODEN: BSECBU; ISSN: 0305-1978, 1986, XP001204870 * |
KUHN, RICHARD ET AL: "The constitution of lycotetraose" CHEMISCHE BERICHTE , 90, 203-18 CODEN: CHBEAM; ISSN: 0009-2940, 1957, XP009040688 * |
LI C ET AL: "Synthesis of diosgenyl alpha-l-rhamnopyranosyl-(1->2)-Äbeta-d-glu copy ranosyl-(1->3)Ü-beta-d-glucopyranosid e (gracillin)" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 306, no. 1-2, January 1998 (1998-01), pages 189-195, XP004204799 ISSN: 0008-6215 * |
SANDROCK, ROBERT W. ET AL: "Fungal sensitivity to and enzymic degradation of the phytoanticipin .alpha.-tomatine" PHYTOPATHOLOGY , 88(2), 137-143 CODEN: PHYTAJ; ISSN: 0031-949X, 1998, XP001204873 * |
ZOU C-C ET AL: "The synthesis of gracillin and dioscin: two typical representatives of spirostanol glycosides" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 338, no. 8, 4 April 2003 (2003-04-04), pages 721-727, XP004417407 ISSN: 0008-6215 * |
Also Published As
Publication number | Publication date |
---|---|
US20070135358A1 (en) | 2007-06-14 |
JP2009513527A (en) | 2009-04-02 |
US20090012013A9 (en) | 2009-01-08 |
EP1644391A2 (en) | 2006-04-12 |
WO2005005449A3 (en) | 2005-04-21 |
AU2004255352A1 (en) | 2005-01-20 |
CA2529358A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2230748C2 (en) | Method for preparing clarithromycin as crystals of form ii | |
JP2546659B2 (en) | Method for producing podophyllotoxin type compound | |
KR970002642B1 (en) | Androstane 17-carboxylic-acid esters, their preparation and medicaments containing them | |
DE69602834T2 (en) | METHOD FOR PRODUCING ANTHRACYCLIN ANTIBIOTICA | |
AU775831B2 (en) | Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
US6150336A (en) | Steroidal glycosides | |
JPS6360031B2 (en) | ||
JPS58219196A (en) | Production of 4'-demethyl-epipodophyllotoxin-beta-d- ethylideneglucoside | |
EP1644391A2 (en) | Steroid modified solatrioses | |
EP1654271B1 (en) | Steroid modified solatrioses | |
JP4267448B2 (en) | Method for synthesizing solanam glycoside | |
AU641644B2 (en) | A process for the preparation of etoposides | |
HU197755B (en) | Process for producing 3-alkoxy-18-methyl-3,5-estradien-17-one or 3-alkoxy-18-methyl-3,5,15-estratrien-17-one derivatives | |
JP2005502671A5 (en) | ||
EP0490311B1 (en) | Derivatives of 10,11,12,13-tetra-hydrodesmycosin, processes for preparation, and use thereof in obtaining pharmaceuticals | |
AU2002336998A1 (en) | Synthesis of solanum glycosides | |
EP0647235B1 (en) | Process for steroidal peracyl glycosides | |
AU2004234071A1 (en) | Synthesis of solanum glycosides | |
US3629299A (en) | 1alpha 3-di lower alkoxy - 21 - carlio-lower alkoxy-pregna - 3 5 - diene and process for the production thereof | |
JPH05345794A (en) | Production of glycosylanthracyclinones | |
HU219347B (en) | 10,11,12,13-tetrahydro-desmycosin derivatives and pharmaceutical compositions containing 4'-deoxy-10,11,12,13-tetrahydro-desmycosin | |
JPH0812696A (en) | New 16-membered ring macrolide derivative and its efficient production | |
JPH06263785A (en) | New glycosyl donor and production of glycoside-based compound using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004255352 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2529358 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004255352 Country of ref document: AU Date of ref document: 20040708 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004255352 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006518156 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004763140 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004763140 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007135358 Country of ref document: US Ref document number: 10563745 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10563745 Country of ref document: US |